Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 11 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

9%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

9Total
Not Applicable (2)
Early P 1 (1)
P 1 (1)
P 2 (4)
P 3 (1)

Trial Status

Recruiting6
Not Yet Recruiting3
Completed1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06545682Phase 1Recruiting

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

NCT07476781Not ApplicableRecruiting

CSF and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and CNS Metastases or no CNS Metastases

NCT07268053Early Phase 1Recruiting

A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases

NCT06888817Phase 3Recruiting

Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

NCT07162246Phase 2Recruiting

Combined Gamma Knife/Linac Radiosurgery for Large Brain Tumors / Metastases

NCT07132203Not ApplicableCompletedPrimary

Magnetic Resonance-Guided Laser Interstitial Thermal Therapy for Brain Metastases Trial

NCT06728150Not Yet Recruiting

Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer

NCT06684873Phase 2Not Yet Recruiting

A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)

NCT06604689Recruiting

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

NCT06586866Phase 2Not Yet Recruiting

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

NCT03288272Phase 2UnknownPrimary

Evaluation of Repeated Whole Brain Radiotherapy Versus Best Supportive Care for Multiple Brain Metastases.

Showing all 11 trials

Research Network

Activity Timeline